Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
The Endocrine Society's Clinical Practice Guideline on pharmacological management of obesity recommends considering AOMs for patients who experience weight regain after bariatric surgery, particularly when lifestyle modifications prove insufficient
:max_bytes(150000):strip_icc()/Health-GettyImages-2153927815-0bf99cd73e2c46908d7fc0973739f6d0.jpg)
A new analysis of the SURMOUNT clinical trials reveals that the medicine, administered as a once-weekly injection, leads to significant weight reduction
Karanikas, MS (Eli Lilly and Company) and Amelia Torcello Gomez, PhD (Eli Lilly and Company) for writing and editorial contributions
In the add-on to basal insulin placebo-controlled study (SURPASS-5), all doses (5, 10 and 15 mg) resulted in significantly greater SBP reductions compared with placebo (ETD [95% CI] 4.4 [ 7.8, 1.0], 6.6 [ 9.9, 3.2] and 10.9 [ 14.3, 7.5] mmHg
This method effectively sidesteps the digestive system, potentially leading to quicker and more visible results
First, appetite is naturally reduced
US$ 23.38
US$ 28.20
US$ 26.27
US$ 27.29
US$ 25.36
US$ 23.20
US$ 29.45
US$ 26.10
US$ 23.38
US$ 20.84
